SCY-635 / SCYNEXIS 
Welcome,         Profile    Billing    Logout  
 17 Diseases   0 Trials   0 Trials   5 News 
  • ||||||||||  SCY-635 / SCYNEXIS
    Journal:  Assessing Trans-Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins. (Pubmed Central) -  Jan 23, 2024   
    A total of 861 and 357 proteins were identified as specifically associated with OATP1B1 and OATP1B3, respectively, including various protein kinases, ubiquitin-related enzymes, the tacrolimus (FK506)-binding proteins FKBP5 and FKBP8, and several known regulatory targets of calcineurin. The current study reports several novel findings that expand our understanding of impaired OATP1B1/3 function; these include preincubation-induced trans-inhibition of OATP1B1/3 by the CNI tacrolimus, greater preincubation-induced inhibition by CsA compared to its non-CNI analogue SCY-635, and association of OATP1B1/3 with various proteins relevant to established and candidate OATP1B1/3 regulatory processes.
  • ||||||||||  SCY-635 / SCYNEXIS
    Enrollment change, Combination therapy:  Study of SCY-635, Pegasys and Copegus in Hepatitis C (clinicaltrials.gov) -  May 28, 2012   
    P2,  N=11, Completed, 
    The current study reports several novel findings that expand our understanding of impaired OATP1B1/3 function; these include preincubation-induced trans-inhibition of OATP1B1/3 by the CNI tacrolimus, greater preincubation-induced inhibition by CsA compared to its non-CNI analogue SCY-635, and association of OATP1B1/3 with various proteins relevant to established and candidate OATP1B1/3 regulatory processes. N=30 --> 11
  • ||||||||||  SCY-635 / SCYNEXIS
    Trial completion, Combination therapy:  Study of SCY-635, Pegasys and Copegus in Hepatitis C (clinicaltrials.gov) -  May 28, 2012   
    P2,  N=11, Completed, 
    N=30 --> 11 Recruiting --> Completed